Literature DB >> 36260116

[Significance of duration of concurrent hormone therapy and definitive radiotherapy].

Dirk Böhmer1, Thomas Wiegel2, Stefan Höcht3, Ute Ganswindt4.   

Abstract

Entities:  

Year:  2022        PMID： 36260116     DOI： 10.1007/s00120-022-01960-y

Source DB:  PubMed          Journal:  Urologie        ISSN： 2731-7064


× No keyword cloud information.
  4 in total

1.  Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.

Authors:  Almudena Zapatero; Araceli Guerrero; Xavier Maldonado; Ana Álvarez; Carmen González-San Segundo; Maria Angeles Cabeza Rodriguez; Victor Macías; Agustí Pedro Olive; Francesc Casas; Ana Boladeras; Carmen Martín de Vidales; Maria Luisa Vázquez de la Torre; Felipe A Calvo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-22       Impact factor: 7.038

2.  High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Authors:  Almudena Zapatero; Araceli Guerrero; Xavier Maldonado; Ana Alvarez; Carmen Gonzalez San Segundo; Maria Angeles Cabeza Rodríguez; Victor Macias; Agustí Pedro Olive; Francesc Casas; Ana Boladeras; Carmen Martín de Vidales; Maria Luisa Vazquez de la Torre; Salvador Villà; Aitor Perez de la Haza; Felipe A Calvo
Journal:  Lancet Oncol       Date:  2015-02-19       Impact factor: 41.316

3.  High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.

Authors:  Almudena Zapatero; Araceli Guerrero; Xavier Maldonado; Ana Álvarez; Carmen González San-Segundo; María Ángeles Cabeza Rodríguez; Josep María Solé; Agustí Pedro Olivé; Francesc Casas; Ana Boladeras; Carmen Martín de Vidales; María Luisa Vázquez de la Torre; Susana Vara; Juan Luis Sanz; Felipe A Calvo
Journal:  Lancet Oncol       Date:  2022-04-12       Impact factor: 41.316

4.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.